## **2024** HAIC Multi-site Gram-negative Surveillance Initiative (MuGSI) Supplemental Surveillance Officer Survey

survey metho	vis to ve ds at cli	erify and inical lab	document o oratories. I	current s Please en	surveillan iter your i	ce proced responses	lures, incluing the co	uding iso orrespon	late colle	ction and DCap dat	testing abase. If
Site: _	CA	CO	CT	_ GA _	MD _	MN _	NM	_ NY _	_ OR _	TN	
								-		pathoger	ıs should
Surve	illance	Area C	haracterist	tics							
	b. c.	specify Carban specify Extendarea, p	y: penem-resis y: led-spectrui lease specif	stant <i>Aci</i> m β-lact fy:	inetobacte	er bauma	nnii (CRA	AB) surv	eillance a	area, pleas	se ance
2.	Is CR	at counties are under surveillance for MuGSI activities at your site?  a. Carbapenem-resistant Enterobacterales (CRE) surveillance area, please specify:  b. Carbapenem-resistant Acinetobacter baumannii (CRAB) surveillance area, please specify:  c. Extended-spectrum β-lactamases-producing Enterobacterales (ESBL-E) surveillance area, please specify:  Invasive Escherichia coli (iEC) surveillance area, please specify:  RE reportable at your state/site? yes no  If yes:  i. Please describe your state reportable definition of CRE:									
	a.	•	Please des	cribe yo	our state r	eportable	definition	of CRE	E:		_
		ii.	Where in y	<mark>your stat</mark>	te is CRE	reportab	<mark>le</mark> ?				
			_			ea, such	as a count	<mark>y(ies).</mark> P	lease spe	ecify	
	d. Invasive Escherichia coli (iEC) surveillance area, please specify:  Is CRE reportable at your state/site? yes no  a. If yes:										
	h	If no:		у	es	no	spo	ecify			
	0.		to have ac	cess to ( A S	CRE <mark>labo</mark> Agent of tl tate Heal	ratory rep ne state th Depart		nedical i	records?		
		ii.	Does your  1. If y		_		RE reporta		_		<mark>ınknown</mark>

Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a current valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Rd NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978)

3. Is CRAB rep	oortable at your state/site? yes no
a. If yes:	Please describe your state reportable definition of CRAB:
ii.	Where in your state is CRAB reportable?
	Statewide Defined area, such as a county(ies). Please specify
	Is isolate submission to the State Health Department Laboratory required? yes no
b. If no: i.	What mechanism do you have in place that allows for SOs to have access to CRAB laboratory reports and medical records?  Agent of the state State Health Department Regulation Other, please explain:
ii.	Does your state/site plan to make CRAB reportable? yes nounknown  1. If yes, when does your state/site plan to make CRAB reportable?
4. Is ESBL-E rep	portable at your state/site? yes no
a. If yes:	Please describe your state reportable definition of ESBL-E:
ii.	Where in your state is ESBL-E reportable?  Statewide Defined area, such as a county(ies). Please specify
iii. b. If no: i.	Is isolate submission to the State Health Department Laboratory required?
ii.	Does your state/site plan to make ESBL-E reportable? yes nounknown  1. If yes, when does your state/site plan to make ESBL-E reportable?

a. If yes i. Please describe your state reportable definition of iEC:  ii. Where in your state is iEC reportable?  Statewide  Defined area, such as a county(ies). Please specify  iii. Is isolate submission to the State Health Department Laboratory required?  yes  no  b. If no:  i. What mechanism do you have in place that allows for SOs to have access to iEC laboratory reports and medical records?  Agent of the state  State Health Department Regulation  Other, please explain:  ii. Does your state/site plan to make iEC reportable? yes no unknown  l. If yes, when does your state/site plan to make IEC reportable?  Laboratory Participation and Isolate Testing – Part 1  1. Please describe the clinical laboratories in the MuGSI catchment area:  a. CRE  i. Proportion of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their automated testing instrument (ATI) or laboratory information system (LIS):  ii. Numerator: Number of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their ATI or LIS:  iii. Denominator: Total number of clinical laboratories instareceive and process specimens from residents of the MuGSI CRE surveillance area:  iv. Please describe how MuGSI CRE surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  b. CRAB  i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  iii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  iii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  iii. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area:  iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):	5. Is iEC reportable at your state/site? yes no	
ii. Where in your state is iEC reportable?		
Statewide Defined area, such as a county(ies). Please specify  iii. Is isolate submission to the State Health Department Laboratory required?  yes	i. Please describe your state reportable definition of iEC:	
Defined area, such as a county(ies). Please specify  iii. Is isolate submission to the State Health Department Laboratory required?  yes no  b. If no:  i. What mechanism do you have in place that allows for SOs to have access to iEC laboratory reports and medical records?  Agent of the state  State Health Department Regulation Other, please explain:  ii. Does your state/site plan to make iEC reportable? yes no unknown 1. If yes, when does your state/site plan to make IEC reportable?  Laboratory Participation and Isolate Testing – Part 1  1. Please describe the clinical laboratories in the MuGSI catchment area:  a. CRE  i. Proportion of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their automated testing instrument (ATI) or laboratory information system (LIS):  ii. Numerator: Number of clinical laboratories serving the muGSI CRE surveillance area with queries installed on their ATI or LIS:  iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRE surveillance area:  iv. Please describe how MuGSI CRE surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  b. CRAB  i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area:  iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  c. ESBL-E	ii. Where in your state is iEC reportable?	
b. If no:    What mechanism do you have in place that allows for SOs to have access to iEC laboratory reports and medical records?   Agent of the state   State Health Department Regulation   Other, please explain:		
b. If no:  i. What mechanism do you have in place that allows for SOs to have access to iEC laboratory reports and medical records?  Agent of the state  State Health Department Regulation Other, please explain:  ii. Does your state/site plan to make iEC reportable?	Defined area, such as a county(ies). Please specify	
b. If no: i. What mechanism do you have in place that allows for SOs to have access to iEC laboratory reports and medical records?  Agent of the state  State Health Department Regulation Other, please explain:  ii. Does your state/site plan to make iEC reportable?yes nounknown I. If yes, when does your state/site plan to make IEC reportable?  Laboratory Participation and Isolate Testing - Part 1  1. Please describe the clinical laboratories in the MuGSI catchment area: a. CRE i. Proportion of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their automated testing instrument (ATI) or laboratory information system (LIS): ii. Numerator: Number of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their ATI or LIS: iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRE surveillance area: iv. Please describe how MuGSI CRE surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  b. CRAB i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS: ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS: iii. Denominator: Total number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS: iii. Denominator: Total number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS: iii. Denominator: Total number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS: iii. Penominator: Total number of clinical laboratories serving the MuGSI CRAB surveillance area: iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):	iii. Is isolate submission to the State Health Department Laboratory required?	
i. What mechanism do you have in place that allows for SOs to have access to iEC laboratory reports and medical records?		
Laboratory reports and medical records?		iEC
State Health Department Regulation Other, please explain:  ii. Does your state/site plan to make iEC reportable?	the contract of the contract o	LC
Other, please explain:  ii. Does your state/site plan to make iEC reportable?	tion of the control o	
ii. Does your state/site plan to make iEC reportable? yes no unknown		
Laboratory Participation and Isolate Testing – Part 1  1. Please describe the clinical laboratories in the MuGSI catchment area: a. CRE i. Proportion of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their automated testing instrument (ATI) or laboratory information system (LIS): ii. Numerator: Number of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their ATI or LIS: iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRE surveillance area: iv. Please describe how MuGSI CRE surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  b. CRAB i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS: ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS: iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area: iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  c. ESBL-E	other, preuse explain.	
Laboratory Participation and Isolate Testing – Part 1  1. Please describe the clinical laboratories in the MuGSI catchment area: a. CRE i. Proportion of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their automated testing instrument (ATI) or laboratory information system (LIS): ii. Numerator: Number of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their ATI or LIS: iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRE surveillance area: iv. Please describe how MuGSI CRE surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  b. CRAB i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS: ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS: iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area: iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  c. ESBL-E		<mark>wn</mark>
<ul> <li>1. Please describe the clinical laboratories in the MuGSI catchment area: <ul> <li>a. CRE</li> <li>i. Proportion of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their automated testing instrument (ATI) or laboratory information system (LIS): <ul> <li>ii. Numerator: Number of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their ATI or LIS: <ul> <li>iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRE surveillance area: <ul> <li>iv. Please describe how MuGSI CRE surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):</li> </ul> </li> <li>b. CRAB <ul> <li>i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS: <ul> <li>ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:</li> <li>iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area: <ul> <li>iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):</li> </ul> </li> <li>c. ESBL-E</li> </ul></li></ul></li></ul></li></ul></li></ul></li></ul>	1. If yes, when does your state/site plan to make IEC reportable?	
<ul> <li>1. Please describe the clinical laboratories in the MuGSI catchment area: <ul> <li>a. CRE</li> <li>i. Proportion of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their automated testing instrument (ATI) or laboratory information system (LIS): <ul> <li>ii. Numerator: Number of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their ATI or LIS: <ul> <li>iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRE surveillance area: <ul> <li>iv. Please describe how MuGSI CRE surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):</li> </ul> </li> <li>b. CRAB <ul> <li>i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS: <ul> <li>ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:</li> <li>iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area: <ul> <li>iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):</li> </ul> </li> <li>c. ESBL-E</li> </ul></li></ul></li></ul></li></ul></li></ul></li></ul>		
<ul> <li>a. CRE  i. Proportion of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their automated testing instrument (ATI) or laboratory information system (LIS):  ii. Numerator: Number of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their ATI or LIS:  iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRE surveillance area:  iv. Please describe how MuGSI CRE surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  b. CRAB  i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area:  iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):</li> <li>c. ESBL-E</li> </ul>	Laboratory Participation and Isolate Testing – Part 1	
<ul> <li>a. CRE  i. Proportion of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their automated testing instrument (ATI) or laboratory information system (LIS):  ii. Numerator: Number of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their ATI or LIS:  iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRE surveillance area:  iv. Please describe how MuGSI CRE surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  b. CRAB  i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area:  iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):</li> <li>c. ESBL-E</li> </ul>	1. Please describe the clinical laboratories in the MuGSI catchment area:	
queries installed on their automated testing instrument (ATI) or laboratory information system (LIS):	a. CRE	
ii. Numerator: Number of clinical laboratories serving the MuGSI CRE surveillance area with queries installed on their ATI or LIS:		with
<ul> <li>ii. Numerator: Number of clinical laboratories serving the area with queries installed on their ATI or LIS:</li></ul>		
<ul> <li>iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRE surveillance area:</li></ul>	ii. Numerator: Number of clinical laboratories serving the MuGSI CRE surveill	ance
specimens from residents of the MuGSI CRE surveillance area:  iv. Please describe how MuGSI CRE surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  b. CRAB  i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area:  iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  c. ESBL-E	1	
<ul> <li>iv. Please describe how MuGSI CRE surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):</li> <li>b. CRAB  <ol> <li>i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:</li> <li>ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:</li> <li>iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area:</li> <li>iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):</li> </ol> </li> <li>c. ESBL-E</li> </ul>		
b. CRAB  i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:  iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area:  iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  c. ESBL-E		here
<ul> <li>i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:</li> <li>ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:</li> <li>iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area:</li> <li>iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):</li> <li>c. ESBL-E</li> </ul>	ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):	
<ul> <li>i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:</li> <li>ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:</li> <li>iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area:</li> <li>iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):</li> <li>c. ESBL-E</li> </ul>	b. CRAB	
<ul> <li>ii. Numerator: Number of clinical laboratories serving the MuGSI CRAB surveillance area with queries installed on their ATI or LIS:</li> <li>iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area:</li> <li>iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):</li> <li>c. ESBL-E</li> </ul>	i. Proportion of clinical laboratories serving the MuGSI CRAB surveillance are	<mark>ea</mark>
surveillance area with queries installed on their ATI or LIS:  Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area:  iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  c. ESBL-E	· · · · · · · · · · · · · · · · · · ·	
<ul> <li>iii. Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI CRAB surveillance area:</li></ul>		
<ul> <li>iv. Please describe how MuGSI CRAB surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):</li> <li>c. ESBL-E</li> </ul>	iii. Denominator: Total number of clinical laboratories that receive and process	
where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):  c. ESBL-E	•	
c. ESBL-E		
1. FIODOLIOII OI CHINCALIADOLAGOLES SCIVINE INCI <mark>VIUUSI ESDL-E SULVEIHANCE ALEA</mark>		
with queries installed on their ATI or LIS:		

		ii.	Numerator: Number of clinical laboratories serving the MuGSI ESBL-E surveillance area with queries installed on their ATI or LIS:
		iii.	Denominator: Total number of clinical laboratories that receive and process specimens from residents of the MuGSI ESBL-E surveillance area:
		iv.	Please describe how MuGSI ESBL-E surveillance is conducted at laboratories where ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):
	d.	iEC	
		1.	Proportion of clinical laboratories serving the MuGSI iEC surveillance area with queries installed on their ATI or LIS:
		ii.	Numerator: Number of clinical laboratories serving the MuGSI iEC surveillance
			area with queries installed on their ATI or LIS:
		iii.	Denominator: Total number of clinical laboratories that receive and process
		iv.	specimens from residents of the MuGSI iEC surveillance area:  Please describe how MuGSI iEC surveillance is conducted at laboratories where
			ATI/LIS queries are not installed (e.g., HL7 messages from LabCorp):
2.	Did an	v labor	atories drop out of participation in 2023? yes no
			ow many?
			these laboratories drop out of participation?
2	In 202	2 4:4 1	on identify additional laboratories, recordless of location, which identify MyCCI
<mark>3.</mark>			ou identify additional laboratories, regardless of location, which identify MuGSI persons who are residents of the MuGSI surveillance area at your site?
<mark>3.</mark>			ou identify additional laboratories, regardless of location, which identify MuGSI persons who are residents of the MuGSI surveillance area at your site?
<mark>3.</mark>	isolate	s from j	persons who are residents of the MuGSI surveillance area at your site?  yes no
<b>3.</b>	isolate:	If yes,	persons who are residents of the MuGSI surveillance area at your site?
3.	isolate:	If yes, If yes,	persons who are residents of the MuGSI surveillance area at your site?  yesno how many?
3.	isolate:	If yes, If yes,	how many?how many of these laboratories were added?
3.	isolate: a. b.	If yes, If yes, i.	how many?how many of these laboratories were added?  If all new laboratories identified were not added, why not?
3.	a. b.	If yes, If yes, i. If yes,	how many?how many of these laboratories were added? If all new laboratories identified were not added, why not?  how did you identify these new laboratories?
3.	a. b.	If yes, If yes, i.  If yes, Approx	bersons who are residents of the MuGSI surveillance area at your site?
3.	a. b.	If yes, If yes, i.  If yes, Approx	how many?how many of these laboratories were added? If all new laboratories identified were not added, why not?  how did you identify these new laboratories?
<ol> <li>3.</li> <li>4.</li> </ol>	a. b. c. d.	If yes, If yes, If yes, Approresider	how many?how many of these laboratories were added? If all new laboratories identified were not added, why not?  how did you identify these new laboratories?  eximately how many cases are identified at the new laboratories each year among that of the MuGSI surveillance area?
	a. b.  c. d.	If yes, If yes, If yes, Appropriate our site serves	bersons who are residents of the MuGSI surveillance area at your site?
	a. b.  c. d.	If yes, If yes, i.  If yes, i.  Approresider our site s yes If yes,	bersons who are residents of the MuGSI surveillance area at your site?  yes
	a. b.  c. d.	If yes, If yes, i.  Appropriate our site suryes If yes, i.	bersons who are residents of the MuGSI surveillance area at your site?
	a. b.  c. d.	If yes, If yes, i.  Appropriate sur site sur sit	how many?how many of these laboratories were added?how many of these laboratories were not added, why not?  how did you identify these new laboratories?  wimately how many cases are identified at the new laboratories each year among atts of the MuGSI surveillance area?  send any MuGSI isolates to CDC for characterization in calendar year 2023? no please describe how your site determines which MuGSI isolates to send to CDC: CRE: CRAB:
	a. b.  C. d.  Did yo  a.	If yes, If yes, i.  If yes, i.  Appropriate sur site sur	bersons who are residents of the MuGSI surveillance area at your site?
	a. b.  C. d.  Did yo  a.	If yes, If yes, If yes, Approresider our site s yes If yes, i. ii. iv. If yes,	how many?how many of these laboratories were added?how many of these laboratories were added, why not?  how did you identify these new laboratories?  kimately how many cases are identified at the new laboratories each year among ats of the MuGSI surveillance area?no  please describe how your site determines which MuGSI isolates to send to CDC: CRE: CRAB: ESBL: iEC: how many clinical laboratories contributed MuGSI isolates:
	a. b.  C. d.  Did yo  a.	If yes, If yes	bersons who are residents of the MuGSI surveillance area at your site?

	iii. ESBL:iv. iEC:
5.	How many isolates with a specimen collection date in 2023 did you expect to be able to collect from the clinical laboratories?  CRE; CRAB; ESBL; iEC
6.	What was the total number of isolates with a specimen collection date in 2023 that were collected from the clinical laboratories?  CRE; CRAB; ESBL; iEC

## **Laboratory Participation and Isolate Testing – Part 2**

Please complete the following information for each clinical laboratory participating in MuGSI surveillance at your site in 2023:

1.	Laboratory ID:
2.	Type of laboratory: clinical laboratorypublic health laboratoryresearch laboratoryreference laboratory
3.	MuGSI pathogen(s) under surveillance: CRECRABESBLiEC
4.	Method for sharing laboratory reports with your site:
	electronic messaging, such as HL7 e-mail fax EIP staff manually generate reports on-site other, please specify unknown
5.	Method for case identification: automated testing instrumentlaboratory information systemmedical recordother, please specifyunknown
6.	Type of ATI and card:

Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a current valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC/ATSDR Reports Clearance Officer; 1600 Clifton Rd NE, MS D-74, Atlanta, Georgia 30329; ATTN: PRA (0920-0978)

## 7. Carbapenem confirmatory testing method

a. Please report the carbapenem confirmatory testing method(s) performed for each MuGSI organism separately.

kirby bauer:	CRE _	CRAB _	ESBL	iEC
other, please specify:	CRE _	CRAB _	ESBL	iEC
laboratory not testing	CRE _	CRAB _	ESBL	iEC
unknown	CRE _	CRAB _	ESBL	iEC

## 8. Carbapenemase testing method

a. Please report the carbapenemase testing method(s) performed for each MuGSI organism separately.

Non-molecular test methods				
carbaNP:	CRE	CRAB	ESBL	iEC
carbapenemase inactivation method:	CRE	CRAB	ESBL	iEC
CPO detect:	CRE	CRAB	ESBL	iEC
disk diffusion/ROSCO disk e-test:	CRE	CRAB	ESBL	iEC
modified carbapenemase inactivation method:	CRE	CRAB	ESBL	iEC
modified hodge test:	CRE	CRAB	ESBL	iEC
RAPIDEC:	CRE	CRAB	ESBL	iEC
Other, please specify:	CRE	CRAB	ESBL	iEC
laboratory not testing:	CRE	CRAB	ESBL	iEC
unknown:	CRE	CRAB	ESBL	iEC
Molecular test methods				

C	in test memous				
	automated molecular assay:	CRE	CRAB	ESBL	iEC
	carba-R:	CRE	CRAB	ESBL	iEC
	check points:	CRE	CRAB	ESBL	iEC
	MALDI-TOF MS:	CRE	CRAB	ESBL	iEC
	next generation nucleic acid sequencing:	CRE	CRAB	ESBL	iEC
	polymerase chain reaction:	CRE	CRAB	ESBL	iEC
	streck ARM-D:	CRE	CRAB	ESBL	iEC
	other, please specify:	CRE	CRAB	ESBL	iEC
	laboratory not testing:	CRE	CRAB	ESBL	iEC
	unknown:	CRE	CRAB	ESBL	iEC

Please report the ESBL production testing method(s) p	3			
broth microdilution – ESBL well:	CRE	CRAB	ESBL	iEC
broth microdilution – ATI flag:	CRE	CRAB	ESBL	iEC
broth microdilution – manual:	CRE	CRAB	ESBL	iEC
disk diffusion:	CRE	CRAB	ESBL	iEC
e-test:	CRE	CRAB	ESBL	iEC
molecular test, please specify:		CRAB	ESBL	iEC
other non-molecular test, please specify:		CRAB	ESBL =	iEC
laboratory not testing:	CRE	CRAB	ESBL =	iEC
unknown:	CRE	CRAB	ESBL	iEC
ism identification method <sup>†</sup> Please report the organism identification method(s) pe				
Please report the organism identification method(s) pe	erformed for each M	uGSI organis	<mark>n separately.</mark>	
Please report the organism identification method(s) possible MALDI-TOF:	erformed for each M  CRE	uGSI organis.	n separately. ESBL	iEC
Please report the organism identification method(s) possible.  MALDI-TOF: polymerase chain reaction:	erformed for each M CRE CRE	uGSI organis CRAB CRAB	n separately. ESBL _ESBL	iEC iEC
Please report the organism identification method(s) possible.  MALDI-TOF: polymerase chain reaction: whole genome sequencing:	erformed for each M	uGSI organis CRAB CRAB CRAB	n separatelyESBLESBLESBL	iEC iEC iEC
Please report the organism identification method(s) per MALDI-TOF: polymerase chain reaction: whole genome sequencing: DNA sequencing, please specify:	erformed for each M	CRABCRABCRABCRABCRABCRABCRAB	ESBL	iEC iEC iEC iEC
Please report the organism identification method(s) per MALDI-TOF: polymerase chain reaction: whole genome sequencing: DNA sequencing, please specify: rRNA gene sequencing, please specify:	erformed for each M	CRAB _	n separately.  ESBL ESBL ESBL ESBL ESBL	iEC _iEC _iEC _iEC _iEC
Please report the organism identification method(s) per MALDI-TOF: polymerase chain reaction: whole genome sequencing: DNA sequencing, please specify: rRNA gene sequencing, please specify: biochemical tests, please specify:	erformed for each M	CRABCRABCRABCRABCRABCRABCRAB	ESBLES	iEC iEC iEC iEC
Please report the organism identification method(s) per MALDI-TOF: polymerase chain reaction: whole genome sequencing: DNA sequencing, please specify: rRNA gene sequencing, please specify: biochemical tests, please specify: immunological techniques, please specify:	CRE	CRAB CRAB CRAB CRAB CRAB CRAB CRAB CRAB	ESBL ESBL ESBL ESBL ESBL ESBL ESBL ESBL	iEC iEC iEC iEC iEC iEC
Please report the organism identification method(s) per MALDI-TOF: polymerase chain reaction: whole genome sequencing: DNA sequencing, please specify: rRNA gene sequencing, please specify: biochemical tests, please specify: immunological techniques, please specify: other, please specify:	CRE	CRABCR	ESBLES	iEC iEC iEC iEC iEC iEC
Please report the organism identification method(s) per MALDI-TOF: polymerase chain reaction: whole genome sequencing: DNA sequencing, please specify: rRNA gene sequencing, please specify: biochemical tests, please specify: immunological techniques, please specify:	erformed for each M	CRAB CRAB CRAB CRAB CRAB CRAB CRAB CRAB	ESBL ESBL ESBL ESBL ESBL ESBL ESBL ESBL	iEC iEC iEC iEC iEC iEC

11. Culture-independent diagnostic test:

yes, please specify the type of test		
If yes, is a positive test result always followed up by a culture? yes	no	unknown
<mark>no</mark> no		
unknown		

12. Isolate submission to state public health laboratory

	recent year a check-in was completed for the laboratory:	
	describe the participating laboratory's policy on maximum duration of referral for antimicrobial susceptibility testing for	
	s of the same MuGSI organism. Successive isolates are defined as two microorgansims with similar identification that whe same patient at two different time points. Please indicate if the policy differs depending on whether successive isolates	
	he same specimen source or different specimen source.	25 WOIC CUIT
	·	
ditional	nformation on MuGSI surveillance activities	
1. Doe	your site complete a survey for any of the following types of facilities:	
	Physician/Outpatient provider: yes no	
	i. If yes, the last survey was completed in:	
ł	i. If yes, the last survey was completed in:	
	i. If yes, the last survey was completed in:	
(	LTACH: yes no	
	i. If yes, the last survey was completed in:	
	Dialysis center: ves no	
(	i. If yes, the last survey was completed in:	
(	1. If yes, the last survey was completed in:	
	Hospital laboratory: yes no	
	Hospital laboratory: yes no	
E	Hospital laboratory: yes no i. If yes, the last survey was completed in:	
. In 20	Hospital laboratory: yes no	

	c. If yes, how many facilities have you identified the clinical laboratory that serves it?
3.	Does your site run a data edit program in addition to the CDC edit program that is sent out monthly? This could include the data edits available on the MuGSI Case Management System dashboard.
	b. If yes, what type of edits are you running? Do you think they would be helpful to add to edits generated by CDC?
4.	Did your site geocode MuGSI cases in 2023? yes no a. If yes, what is the most recent year of surveillance data that was geocoded? b. If no, why not?
5.	Did your site match MuGSI cases to the state vital statistics death registry in 2023? yes no a. If yes, what is the most recent year of surveillance data that was matched? b. If no, why not?
<u>6.</u>	Did your site complete CRF re-abstractions in 2023? yes no a. If yes, what was the most recent year of surveillance data with CRFs re-abstracted?
	b. If no, why not?
7.	What is the IRB determination for MuGSI at your site?ResearchNon-ResearchOtherUnknown

